The Conference Room with Simon Lader
The answer lives in this podcast

Answer extracted from The Conference Room with Simon Lader — listen to the full episode below.

🎧 Listen to the episode on Listenly

What early challenges did Dr. Sherry Zhang face as an immigrant pursuing higher education in the United States?

Dr. Sherry Zhang's visa was rejected three times before she could start her PhD at Marquette University in Wisconsin, forcing her to arrive late to her program start date. Her parents purchased a one-way ticket to support her attempt, demonstrating the sacrifice and determination required to overcome immigration barriers to higher education in the United States.

Arriving in Wisconsin with minimal financial resources—just three bags and $3,000 from her parents—Zhang faced not only bureaucratic obstacles but also environmental challenges. Wisconsin's harsh winter winters presented a stark contrast to her expectations, yet she discovered the university community to be unexpectedly warm and welcoming.

As Zhang explains in the episode, this early environment became foundational to her scientific training and would later fuel her entrepreneurial journey. The acceptance and support she found at Marquette, despite arriving as a first-generation immigrant with limited resources, shaped her approach to building inclusive communities in her own work.

"This drive in me to deliver world-class science and translate that into something useful and practical for everyday people is so strong that I think that will motivate me to learn new skills, to meet new people, to get on stage that I'll be nervous for, and raise funding."

Sherry Zhang — Executive Director of External Strategy and Partnerships at Price Lab at Buck Institute for Research on Aging, molecular biologist, and founder of Genopalate. After earning her PhD in molecular biology from Marquette University, she conducted research at Medical College of Wisconsin (MCW) studying obesity genomics. Zhang founded Genopalate, a DNA-based personalized nutrition company that has served more than 170,000 customers, and currently leads AI-driven health optimization research focused on extending human lifespan.

The visa rejection process itself reveals the systemic barriers many international students face. Three denials required persistence and family financial support that most aspiring students cannot access. Zhang's parents' decision to purchase a one-way ticket—rather than a round-trip ticket that might suggest her departure—represented both a vote of confidence and a risk, signaling their commitment to her success in the United States.

What makes Zhang's story particularly instructive is how she transformed these early hardships into fuel for ambition. The combination of immigration challenges, financial constraints, and environmental adaptation—arriving in one of the coldest American states—could have deterred her. Instead, as discussed at length in this podcast, she credits that difficult transition period with building the resilience and work ethic that would define her later achievements in both academia and entrepreneurship.

If you want to understand how Zhang navigated the early rejection and what specific skills she developed during her PhD years that prepared her to launch Genopalate and eventually lead research at one of the world's leading aging research institutions, the full episode offers far more detail about her journey.

See also

What is the vision behind the new AI-native health platform Dr. Sherry Zhang is building at Buck Institute?

Rather than asking the reactive question 'What's wrong with you today,' the platform asks proactive questions like 'Where is your health headed?' and helps users understand their health trajectory before problems emerge.

How should founders structure internal communication to avoid meeting overload while maintaining alignment?

Dr. Zhang implements a cadenced communication structure: daily standups of 15 minutes for urgent issues and blockers; weekly touchbase meetings around company progress and vision alignment.

What is the minimum viable product strategy for early-stage biotech companies?

Founders must listen deeply to their first and second customer personas, then build a product in a lean way by identifying the minimal viable product that solves their core problem.

Listen to the episode on Listenly